Sorrento Completes Suzhou Manufacturing Plant for ADC Drugs

Sorrento Therapeutics, a San Diego-Nanjing company developing antibody drug conjugates, completed construction of a 25,000 square foot GMP manufacturing facility in Suzhou. The facility is run by Sorrento's subsidiary, Levena Biopharma, which is also in charge of Sorrento's 12 ADC partnerships with global biopharmas. The company said the facility, which has state-of-the-art equipment for the difficult process development and manufacturing of ADC drugs, will also provide supplies of two wholly-owned Sorrento ADC molecules that are close to IND stage. More details.... Stock Symbol: (NSDQ: SRNE) Share this with colleagues: // //